• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation
experience cardiovascular complications. Additional treatments are needed to reduce these …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with
combination of several drugs as the cornerstone for symptomatic and prognostic …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Background: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure–
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Abstract Background Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-
transporter 2 inhibitors favorably influence the clinical course of patients with heart failure …